Pharmaceutical opinion : **Interaction between Digoxin and anti-HCV**

Patient : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ DOB \_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_ Telephone : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

After analyzing your patient's file, I noticed a problem with his medication.

**Glecaprevir / Pibrentasvir (Maviret)**   **and** Digoxin (Lanoxin)

**Interaction mechanism :** An increased risk of adverse effects from digoxin may occur when co-administered with the above-mentioned anti-HCV drugs. The elimination of digoxin involves P-gp transporter which is inhibited by some anti-HCVs.

***Glecaprevir / Pibrentasvir (Maviret) and digoxin***

Additional information:

* Glecaprevir / Pibrentasvir (Maviret) + digoxin 0.5 mg mg die : ↑ 48% Digoxin AUC.
* **Product monograph suggests reducing the dose by approximately 50% or changing the dosing frequency while continuing to monitor.**

Possible therapeutic options (Digoxin) :

If digoxin is added to existing anti-HCV therapy.

* If combination is necessary, start digoxin with a small dose and then gradually increase depending on efficacy and tolerance.

If the patient is already on digoxin and the anti-HCV therapy is started

* If combination is needed, decrease the current dose of digoxin and gradually increase the dose according to digoxinemia, efficacy and tolerance.
* Keep the current dose and closely monitor the side effects associated with digoxin.

Patient currently on treatment with this association and tolerating it

* Keep this combination and closely monitor any adverse effects that may occur.
* Perform a control digoxinemia.
* A control ECG could be done, especially in patients with a risk of QT prolongation. Be sure to correct electrolyte disturbances.

**Suggested dosage :**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ REN : \_\_\_\_\_\_\_

* Other :\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ REN : \_\_\_\_\_\_\_

**Follow-up :** Monitor the side effects of digoxin and perform digoxinemia monitoring. According to the clinician's judgment, an ECG and electrolyte balance could be done.

Do not hesitate to contact us for additional information.
In collaboration,

Pharmacist : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Telephone : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_​ Fax : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

As a prescription, date and sign:

Date : \_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_ Signature and licence : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_